CLIENT LOGIN
Investors2021-05-13T14:13:15-07:00
FOR INVESTORS

News, events, and reports.


Investor Presentations

Recent Healthcare Conferences

View our presentations

Scientific Evidence

MammaPrint and BluePrint Utility

View our Landmark Trials

Reach out to our investor relations department.

Contact Us

Recent Events & News

Healthcare Conferences

Agendia’s leadership team presents at healthcare conferences globally to share updates on the company and our vision for how we fit into the breast cancer treatment space

View Presentations Here

MINDACT Update

Long term follow up data for the EORTC’s landmark MINDACT trial were presented at major conferences in 2020 and confirm MammaPrint’s utility for women with breast cancer

View Data Here

NBRST Update

Five-year follow up data for Agendia’s prospective NBRST trial were presented at SABCS 2020 and confirm the utility of our tests for pre-operative treatment planning

View Data Here

SABCS 2020

Agendia will present new data from ongoing clinical research evaluating the MammaPrint and BluePrint genomic tests at the upcoming […]

View More Information
Two women reading about genomic breast cancer results

Latest News

Agendia Presents New Data Demonstrating MammaPrint’s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients […]

Read The Article
I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go “beyond the mammogram” in a portrait series illustrating people touched by breast cancer.

View The Documentary

Investor News

912, 2021

Agendia Presents Data at SABCS 2021 Showing MammaPrint and BluePrint More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors

December 9th, 2021|

ER+ tumors reclassified by BluePrint as Basal-type occur at a higher frequency in Black women compared to White women Understanding tumor biological differences via MammaPrint and BluePrint and will drive better, more personalized care   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 9, 2021 – Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data from a research collaboration with Vanderbilt University Medical Center demonstrating the capability of MammaPrint® and BluePrint® to identify differences in recurrence risk and tumor classification amongst different racial groups at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021). The presentation, titled MammaPrint and BluePrint identify genomic differences in HR+ HER2- breast cancers from young Black and White women, highlights Read More

706, 2021

Agendia’s MammaPrint Test is the First to Demonstrate the Ability to Predict Benefit from Extended Endocrine Treatment in NSABP B-42 Trial

June 7th, 2021|

MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy MammaPrint testing for endocrine management decisions will be available in the US and the rest of the world as early as Q3 2021 June 07, 2021 05:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced positive results from an analysis using its 70-gene MammaPrint® assay on samples from the NSABP B-42 trial. These results were reported as an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract, titled “Utility of the 70-gene MammaPrint assay for prediction of benefit Read More

506, 2021

Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers

June 5th, 2021|

Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk June 05, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation. The presentation will detail an additional risk threshold previously established within the MammaPrint Low Risk category, identifying patients with an Ultra Low Risk of distant recurrence, essentially meaning the patient’s tumor is very unlikely to recur or metastasize over at Read More

406, 2021

Agendia Presents Data from Innovative FLEX Study at ASCO 2021 Showing MammaPrint and BluePrint Utility in Wide Variety of Patient Populations

June 4th, 2021|

Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate abstract shows MammaPrint reclassified 57% of Oncotype results in tumors from African American patients as higher risk Data presented highlights need for genomic information that is representative of and effective for diverse patient groups June 04, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data from the national FLEX registry that identify differences Read More

406, 2021

ASCO 2021 Podium Presentation on Agendia FLEX Study Shows Clinical & Molecular Differences in Tumors of African American and Caucasian Patients with HR+ Breast Cancer, Underscores Importance of Genomic Insights to Understand Disparities in Outcomes

June 4th, 2021|

Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry Separate abstract shows MammaPrint reclassified 57% of Oncotype results in tumors from African American patients as higher risk Data presented highlights need for genomic information that is representative of and effective for diverse patient groups June 04, 2021 08:00 AM Eastern Daylight Time IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., a world leader in precision oncology for breast cancer, announced today that an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting revealed new data from the national FLEX registry that identify differences Read More

2804, 2021

Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer

April 28th, 2021|

Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe Research Triangle Park, NC, USA, Cambridge, UK, Irvine, Calif., and Amsterdam – 28 April 2021 – Inivata, a leader in liquid biopsy, today announced it has entered a commercialization agreement with Agendia, Inc., a leader in precision oncology for breast cancer. Under the terms of the agreement, Agendia will gain co-exclusive rights to distribute Inivata’s RaDaR® liquid biopsy assay for the detection of Minimal Residual Disease (MRD) and early detection of relapse in patients with breast cancer in North America and Europe, with the option of extending territories over time. It is expected that the RaDaR assay will be reimbursed Read More

Go to Top